Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences.
BACKGROUND: We investigated the prognostic role of tumour-associated macrophages (TAMs) in patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT). METHODS: The expression of CD68+, CD163+ and CD11b+ cells was assessed using immunohistochemistry in...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cancer Research UK
2014
|
| _version_ | 1826288060053061632 |
|---|---|
| author | Balermpas, P Rödel, F Liberz, R Oppermann, J Wagenblast, J Ghanaati, S Harter, P Mittelbronn, M Weiss, C Rödel, C Fokas, E |
| author_facet | Balermpas, P Rödel, F Liberz, R Oppermann, J Wagenblast, J Ghanaati, S Harter, P Mittelbronn, M Weiss, C Rödel, C Fokas, E |
| author_sort | Balermpas, P |
| collection | OXFORD |
| description | BACKGROUND: We investigated the prognostic role of tumour-associated macrophages (TAMs) in patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT). METHODS: The expression of CD68+, CD163+ and CD11b+ cells was assessed using immunohistochemistry in n=106 pre-treatment tumour biopsy samples and was correlated with clinicopathological characteristics, including T-stage, N-stage, grading, tumour localisation, age and sex as well as local failure-free survival (LFFS), distant metastases-free survival (DMFS), progression-free (PFS), and overall survival (OS). Finally, TAMs expression and vessel density (CD31) were examined in n=12 available early local recurrence samples and compared with their matched primary tumours . The diagnostic images and radiotherapy plans of these 12 patients were also analysed. All local recurrences occurred in the high radiation dose region (⩾70 Gy). RESULTS: With a median follow-up of 40 months, OS at 2 years was 60.5%. High CD163 expression in primary tumours was associated with decreased OS (P=0.010), PFS (P=0.033), LFFS (P=0.036) and DMFS (P=0.038) in multivariate analysis. CD163 demonstrated a strong prognostic value only in human papillomavirus (p16(INK4))-negative patients. Early local recurrence specimens demonstrated a significantly increased infiltration of CD11b+ myeloid cells (P=0.0097) but decreased CD31-positive vessel density (P=0.0004) compared with their matched primary samples. CONCLUSIONS: Altogether, baseline CD163 expression predicts for an unfavourable clinical outcome in HNSCC after definitive CRT. Early local recurrences showed increased infiltration by CD11b+ cells. These data provide important insight on the role of TAMs in mediating response to CRT in patients with HNSCC. |
| first_indexed | 2024-03-07T02:08:01Z |
| format | Journal article |
| id | oxford-uuid:9fa71eda-414f-4057-8c25-5865cffd7ae2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:08:01Z |
| publishDate | 2014 |
| publisher | Cancer Research UK |
| record_format | dspace |
| spelling | oxford-uuid:9fa71eda-414f-4057-8c25-5865cffd7ae22022-03-27T00:59:32ZHead and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9fa71eda-414f-4057-8c25-5865cffd7ae2EnglishSymplectic Elements at OxfordCancer Research UK2014Balermpas, PRödel, FLiberz, ROppermann, JWagenblast, JGhanaati, SHarter, PMittelbronn, MWeiss, CRödel, CFokas, EBACKGROUND: We investigated the prognostic role of tumour-associated macrophages (TAMs) in patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT). METHODS: The expression of CD68+, CD163+ and CD11b+ cells was assessed using immunohistochemistry in n=106 pre-treatment tumour biopsy samples and was correlated with clinicopathological characteristics, including T-stage, N-stage, grading, tumour localisation, age and sex as well as local failure-free survival (LFFS), distant metastases-free survival (DMFS), progression-free (PFS), and overall survival (OS). Finally, TAMs expression and vessel density (CD31) were examined in n=12 available early local recurrence samples and compared with their matched primary tumours . The diagnostic images and radiotherapy plans of these 12 patients were also analysed. All local recurrences occurred in the high radiation dose region (⩾70 Gy). RESULTS: With a median follow-up of 40 months, OS at 2 years was 60.5%. High CD163 expression in primary tumours was associated with decreased OS (P=0.010), PFS (P=0.033), LFFS (P=0.036) and DMFS (P=0.038) in multivariate analysis. CD163 demonstrated a strong prognostic value only in human papillomavirus (p16(INK4))-negative patients. Early local recurrence specimens demonstrated a significantly increased infiltration of CD11b+ myeloid cells (P=0.0097) but decreased CD31-positive vessel density (P=0.0004) compared with their matched primary samples. CONCLUSIONS: Altogether, baseline CD163 expression predicts for an unfavourable clinical outcome in HNSCC after definitive CRT. Early local recurrences showed increased infiltration by CD11b+ cells. These data provide important insight on the role of TAMs in mediating response to CRT in patients with HNSCC. |
| spellingShingle | Balermpas, P Rödel, F Liberz, R Oppermann, J Wagenblast, J Ghanaati, S Harter, P Mittelbronn, M Weiss, C Rödel, C Fokas, E Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. |
| title | Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. |
| title_full | Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. |
| title_fullStr | Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. |
| title_full_unstemmed | Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. |
| title_short | Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. |
| title_sort | head and neck cancer relapse after chemoradiotherapy correlates with cd163 macrophages in primary tumour and cd11b myeloid cells in recurrences |
| work_keys_str_mv | AT balermpasp headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT rodelf headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT liberzr headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT oppermannj headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT wagenblastj headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT ghanaatis headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT harterp headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT mittelbronnm headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT weissc headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT rodelc headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences AT fokase headandneckcancerrelapseafterchemoradiotherapycorrelateswithcd163macrophagesinprimarytumourandcd11bmyeloidcellsinrecurrences |